$FENC
FENNEC PHARMACEUTICALS INC.

2015 Q2 Form 10-Q Financial Statement

#000114420415048170 Filed on August 11, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $500.0K $860.0K $510.0K
YoY Change -41.86% 132.43% 41.67%
% of Gross Profit
Research & Development $54.00K $72.00K $24.00K
YoY Change -25.0% -87.0% -86.52%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $54.00K $72.00K $24.00K
YoY Change -25.0% -92.23% -86.52%
Operating Profit -$930.0K -$537.0K
YoY Change 0.32% 0.0%
Interest Expense $390.0K $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $376.0K $180.0K -$2.657M
YoY Change 108.89% -97.61% -25.6%
Pretax Income -$170.0K -$750.0K -$3.190M
YoY Change -77.33% -111.35% -22.38%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$173.0K -$750.0K -$3.194M
YoY Change -76.93% -111.35% -22.25%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02 -$0.08 -$0.33
Diluted Earnings Per Share -$0.02 -$0.08 -$0.33
COMMON SHARES
Basic Shares Outstanding 10.83M shares 9.846M shares 9.769M shares
Diluted Shares Outstanding 10.83M shares 9.846M shares 9.769M shares

Balance Sheet

Concept 2015 Q2 2014 Q2 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.850M $1.020M $1.340M
YoY Change 81.37% 0.99% -29.47%
Cash & Equivalents $1.854M $1.015M $1.338M
Short-Term Investments
Other Short-Term Assets $10.00K $40.00K $3.000K
YoY Change -75.0% 1233.33% -92.5%
Inventory
Prepaid Expenses $54.00K
Receivables
Other Receivables
Total Short-Term Assets $1.870M $1.050M $1.400M
YoY Change 78.1% 1.94% -27.84%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 -$5.000K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.870M $1.050M $1.400M
Total Long-Term Assets $0.00 $0.00 -$5.000K
Total Assets $1.870M $1.050M $1.395M
YoY Change 78.1% 1.94% -28.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $340.0K $154.0K
YoY Change 17.65% -52.51% -78.0%
Accrued Expenses $50.00K $40.00K $57.00K
YoY Change 25.0% -38.46% -36.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $760.0K $5.710M $5.729M
YoY Change -86.69% 65.03% -47.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $760.0K $5.710M $5.729M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $760.0K $5.710M $5.729M
YoY Change -86.69% 65.08% -47.92%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $106.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.112M -$4.658M -$4.334M
YoY Change
Total Liabilities & Shareholders Equity $1.870M $1.050M $1.395M
YoY Change 78.1% 1.94% -28.09%

Cashflow Statement

Concept 2015 Q2 2014 Q2 2014 Q1
OPERATING ACTIVITIES
Net Income -$173.0K -$750.0K -$3.194M
YoY Change -76.93% -111.35% -22.25%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$511.0K -$410.0K -$378.0K
YoY Change 24.63% -53.88% -7.13%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $87.00K
YoY Change
Debt Paid & Issued, Net $0.00 $0.00
YoY Change
Cash From Financing Activities $449.0K $87.00K $53.00K
YoY Change 416.09%
NET CHANGE
Cash From Operating Activities -$511.0K -$410.0K -$378.0K
Cash From Investing Activities $0.00 $0.00 $0.00
Cash From Financing Activities $449.0K $87.00K $53.00K
Net Change In Cash -$62.00K -$323.0K -$325.0K
YoY Change -80.8% -63.67% -20.15%
FREE CASH FLOW
Cash From Operating Activities -$511.0K -$410.0K -$378.0K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$410.0K -$378.0K
YoY Change -53.88% -7.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9846000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12953000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9846000 shares
CY2014Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2015Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1005000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2477000 USD
CY2014Q2 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2015Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-62000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-323000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1916000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1015000 USD
us-gaap Net Income Loss
NetIncomeLoss
4000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3944000 USD
CY2015Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2015Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-511000 USD
CY2014Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-410000 USD
CY2015Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
449000 USD
CY2014Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
87000 USD
CY2015Q2 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-17000 USD
CY2014Q2 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-29000 USD
CY2015Q2 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1000 USD
CY2014Q2 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6000 USD
CY2014Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
180000 USD
CY2014Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-21000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
129000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-929000 USD
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10830000 shares
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9846000 shares
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10830000 shares
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9846000 shares
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10718000 shares
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1010000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-2474000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1663000 USD
CY2015Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
17000 USD
CY2015Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-453000 USD
CY2015Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
449000 USD
CY2014Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
87000 USD
CY2014Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
10000 USD
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
339000 USD
CY2015Q2 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1338000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
472000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-788000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-648000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
476000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
140000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
476000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
140000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-34000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-56000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-14000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
93000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
122000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-83000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-96000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-4957000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-1455000 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140000 USD
CY2014 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
21000 USD
CY2014 fencf Exchange Of Warrants
ExchangeOfWarrants
840000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
1845000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-2176000 USD
CY2015Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
826000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1854000 USD
CY2015Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
309000 USD
CY2015Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2594000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Use of estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting period.&#160;Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation.&#160;Actual results could differ from those estimates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In the opinion of management, these unaudited interim condensed consolidated financial statements include all normal and recurring adjustments, considered necessary for the fair presentation of the Company&#8217;s financial position at June 30, 2015, and to state fairly the results for the periods presented. The most significant estimates included in these financial statements are the derivative instruments described in Note 3. There were significant changes in their valuation during the quarter ended, and for the six-month period ended June 30, 2015.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1854000 USD
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2307000 USD
CY2015Q2 us-gaap Cash
Cash
71000 CAD
CY2015Q2 us-gaap Cash
Cash
69000 USD
CY2015Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
309000 USD
CY2015Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
694000 USD
CY2014Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1319000 USD
CY2014Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
3499000 USD
CY2014Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
5336000 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2015Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.82
CY2015Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
10000 USD
CY2014Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
339000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
19000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
601000 USD
CY2015Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1307000 USD
CY2015Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.32
CY2010Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
6666000 shares
CY2010Q2 fencf Percentage Of Common Shares Outstanding
PercentageOfCommonSharesOutstanding
0.25 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0190 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.27 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.39 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0067 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.25 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0200 pure
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001211583
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
FENCF
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10919218 shares
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54000 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
104000 USD
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2014Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10919000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10593000 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10919000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10593000 shares
CY2015Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
10000 USD
CY2014Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
4000 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
4000 USD
CY2015Q2 fencf Exchange Of Warrants
ExchangeOfWarrants
449000 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2015Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2014Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2235000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares

Files In Submission

Name View Source Status
0001144204-15-048170-index-headers.html Edgar Link pending
0001144204-15-048170-index.html Edgar Link pending
0001144204-15-048170.txt Edgar Link pending
0001144204-15-048170-xbrl.zip Edgar Link pending
fencf-20150630.xml Edgar Link completed
fencf-20150630.xsd Edgar Link pending
fencf-20150630_cal.xml Edgar Link unprocessable
fencf-20150630_def.xml Edgar Link unprocessable
fencf-20150630_lab.xml Edgar Link unprocessable
fencf-20150630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v416858_10q.htm Edgar Link pending
v416858_ex31-1.htm Edgar Link pending
v416858_ex31-2.htm Edgar Link pending
v416858_ex32-1.htm Edgar Link pending
v416858_ex99-1.htm Edgar Link pending